Cardiac troponin I: Is it a marker to detect cordiotoxicity in children treated with doxorubicin?

Turkish Journal of Pediatrics

Volumn 47, Issue 1, 2005, Pages 17-22

  Köseoǧlu, Vedat ^a   Berberoǧlu, Semha ^b   Karademir, Selmin ^c   Kismet, Erol ^a   Yurttutan, Neval ^d   Demirkaya, Erkan ^a   Sungur, Metin ^c   Alehan, Dursun ^d  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

^b ANKARA ONCOLOGY HOSPITAL   (Turkey)

^c DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

^d HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiac troponin I; Cardiotoxicity; Doxorubicin

Indexed keywords

ANTHRACYCLINE; DOXORUBICIN; TROPONIN I;

ADOLESCENT; ADULT; ARTICLE; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DISEASE MARKER; DOSE RESPONSE; ECHOCARDIOGRAPHY; EWING SARCOMA; FEMALE; HEART MUSCLE INJURY; HIGH RISK PATIENT; HUMAN; MALE; MESENCHYMOMA; NEUROECTODERM TUMOR; OSTEOSARCOMA; RHABDOMYOSARCOMA; SOLID TUMOR;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; BIOLOGICAL MARKERS; BONE NEOPLASMS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART; HUMANS; MALE; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; TROPONIN I;

EID: 17844369693     PISSN: 00414301     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Tolba KA, Deliargyris EN. Cardiotoxocity of cancer therapy. Cancer Invest 1999; 17: 408-422.
2. Iacuone JJ, Steinherz L, Oblender MG, Barnard DR, Ablin AR. Modifications fortoxicity. In: Ablin AR (ed). Supportive Care of Children with Cancer (2nd ed). Baltimore: The Johns Hopkins University Press; 1997: 79-109.
3. Steinherz LJ, Graham T, Hurwitz R, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89: 942-949.
4. Bossi G, Lanzarini L, Laudisa ML, Klersy C, Raisaro A, Arico M. Echocardiographic evaluation of patients cured of childhood cancer: a single center study of 117 subjects who received anthracyclines. Med Pediatr Oncol 2001; 36: 593-600.
5. Galvani M, Ottani F, Ferrini D, et al. Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina. Circulation 1997; 95: 2053-2059.
6. Chapelle JP. Cardiac troponin I and troponin T: recent players in the field of myocardial markers. Clin Chem Lab Med 1999;37: 11-20.
7. Panteghini M, Cuccia C, Bonett iG, Giubbini R, Pagani F, Bonini E. Single-point cardiac troponin T at coronary care unit discharge after myocardial infarction correlates with infarct size and ejection fraction. Clin Chem 2002; 48: 1432-1436.
8. Missov E, Calzolari C, Pau B. Circulating cardiac troponin I in severe congestive heart failure. Circulation 1997; 96: 2953-2958.
9. Cardinale D, Sandri MT, Martinoni A, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol 2000; 36: 517-522.
10. Sabatine MSZ, Morrow DA, de Lemos JA, et al. Multimarker approach to risk statification in non-ST elevation acute coronary syndromes: simultaneous assessment ofm troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002; 105: 1760-1763.
11. Saparano JA, Brown DL, Wolff AC. Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers. Drug Saf 2002; 25: 301-311.
12. Giannuzzi P, Temporelli PL, Bosimini E, et al. Indrependent and incremental prognostic value of Doppler-derived initial deceleration time of early filling in both symptomatic and asymptomatic patients with left ventricular dysfunction. J Am Coll Cardiol 1996; 28: 383-390.
13. Marchandise B, Schroeder E, Bosly A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118; 92-98.
14. Steinherz LJ, Steinherz PG, Tan CT, et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
15. Lipshultz SE, Rifai N, Sallan SE, et al. Predictive value of cardiac troponin T in pediatric patients at risk formyocardial injury. Circulation 1997; 96: 2641-2648.
16. Missov E, Calzolari C, Davy JM, Leclercq F, Rossi M, Pau B. Cardiac troponin I in patients with hematologic malignancies. Coron Artery Dis 1997; 8: 537-541.
17. Seino Y, Tomita Y, Nagai Y, et al. Cardioprotective effects of ACE-inhibitor (cilazapril) on adriamycin cardiotoxicity in spontaneously hypertensive rats. Circulation 1993; 88: 633.
18. Herman EH, Zhang J, Lipshultz SE, et al. Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 1999; 17: 2237-2243.
19. Kismet E, Varan A, Ayabakan C, Alehan D, Portakal O, Büyükpamukçu M. Serum troponin T levels and echocardiographic evaluation in children treated with doxorubicin. Med Pediatr Oncol 2003; (In press).